Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

被引：0

作者：

Mats Någård

Mei-Lin Ah-See

Karen So

Marit Vermunt

Fiona Thistlethwaite

Mariette Labots

Patricia Roxburgh

Alain Ravaud

Mario Campone

Liselot Valkenburg-van Iersel

Lone Ottesen

Yan Li

Ganesh Mugundu

机构：

[1] R&D Clinical Pharmacology and Safety Sciences,Clinical Pharmacology and Quantitative Pharmacology

[2] AstraZeneca,Late Stage Development, Oncology R&D

[3] AstraZeneca,Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D

[4] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences

[5] The Christie NHS Foundation Trust and University of Manchester,undefined

[6] Cancer Center Amsterdam,undefined

[7] Amsterdam UMC,undefined

[8] Beaston West of Scotland Cancer Centre and University of Glasgow,undefined

[9] Bordeaux University Hospital,undefined

[10] ICO – Site René,undefined

[11] Maastricht University Medical Centre,undefined

[12] AstraZeneca,undefined

[13] AstraZeneca,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2020年 / 86卷

关键词：

Adavosertib; Food effect; Pharmacokinetics; Oncology; WEE1;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：97 / 108

页数：11

共 50 条

[31] The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
Sunil Sharma
Carolyn D. Britten
Joanne Mortimer
Swarupa Kulkarni
Michelle Quinlan
Angela Liu
Jeffrey W. Scott
Daniel George
Cancer Chemotherapy and Pharmacology, 2014, 74 : 867 - 874
[32] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
Schwartz, Gary K.
Carvajal, Richard D.
Midgley, Rachel
Rodig, Scott J.
Stockman, Paul K.
Ataman, Ozlem
Wilson, David
Das, Shampa
Shapiro, Geoffrey I.
INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 370 - 380
[33] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
Gary K. Schwartz
Richard D. Carvajal
Rachel Midgley
Scott J. Rodig
Paul K. Stockman
Ozlem Ataman
David Wilson
Shampa Das
Geoffrey I. Shapiro
Investigational New Drugs, 2013, 31 : 370 - 380
[34] An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors
Yoshito Komatsu
Tsuneo Shimokawa
Kohei Akiyoshi
Masato Karayama
Akihiko Shimomura
Yasuyuki Kawamoto
Satoshi Yuki
Yuichi Tambo
Kazuo Kasahara
Investigational New Drugs, 2022, 40 : 1011 - 1020
[35] An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors
Komatsu, Yoshito
Shimokawa, Tsuneo
Akiyoshi, Kohei
Karayama, Masato
Shimomura, Akihiko
Kawamoto, Yasuyuki
Yuki, Satoshi
Tambo, Yuichi
Kasahara, Kazuo
INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1011 - 1020
[36] Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors
Goel, Varun
Hurh, Eunju
Stein, Andrew
Nedelman, Jerry
Zhou, Jocelyn
Chiparus, Ovidiu
Huang, Pai-Hsi
Gogov, Sven
Sellami, Dalila
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 745 - 755
[37] Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors
Varun Goel
Eunju Hurh
Andrew Stein
Jerry Nedelman
Jocelyn Zhou
Ovidiu Chiparus
Pai-Hsi Huang
Sven Gogov
Dalila Sellami
Cancer Chemotherapy and Pharmacology, 2016, 77 : 745 - 755
[38] A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
Kerklaan, B. Milojkovic
Slater, S.
Flynn, M.
Greystoke, A.
Witteveen, P. O.
Megui-Roelvink, M.
de Vos, F.
Dean, E.
Reyderman, L.
Ottesen, L.
Ranson, M.
Lolkema, M. P. J.
Plummer, R.
Kristeleit, R.
Evans, T. R. J.
Schellens, J. H. M.
INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 329 - 337
[39] A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
B. Milojkovic Kerklaan
S. Slater
M. Flynn
A. Greystoke
P. O. Witteveen
M. Megui-Roelvink
F. de Vos
E. Dean
L. Reyderman
L. Ottesen
M. Ranson
M. P. J. Lolkema
R. Plummer
R. Kristeleit
T. R. J. Evans
J. H. M. Schellens
Investigational New Drugs, 2016, 34 : 329 - 337
[40] Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors
Nakamichi, Shinji
Nokihara, Hiroshi
Yamamoto, Noboru
Yamada, Yasuhide
Fujiwara, Yutaka
Tamura, Yosuke
Wakui, Hiroshi
Honda, Kazunori
Mizugaki, Hidenori
Kitazono, Satoru
Tanabe, Yuko
Asahina, Hajime
Yamazaki, Naoya
Suzuki, Shigenobu
Matsuoka, Mieko
Ogita, Yoshitaka
Tamura, Tomohide
INVESTIGATIONAL NEW DRUGS, 2015, 33 (03) : 641 - 651

← 1 2 3 4 5 →